Composition for regulating production of interfering ribonucleic acid

{
  "publication_number": "US2026103711A1",
  "country": "US",
  "kind": "A1",
  "title": "Composition for regulating production of interfering ribonucleic acid",
  "abstract": "The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid (RP) and one or more sequences of micro-interfering ribonucleic acid (miRNA). When the RP interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.",
  "claims": [
    "1. A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO. 3. 2. The composition of claim 1, wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof. 3. (canceled) 4. (canceled) 5. (canceled) 6. (canceled)"
  ],
  "description_excerpt": "The present disclosure generally relates to compositions for regulating production of micro-interfering ribonucleic acid (miRNA). In particular, the present disclosure relates to compositions for regulating gene expression and as a result, the production of miRNA that will suppress cytokine over-expression or mis-expression.\n\nBioactive molecules, including cytokines, are necessary for the homeostatic control of biological systems.\n\nWhen bioactive molecules are over-expressed or mis-expressed, homeostasis is lost, and disease is often the result.\n\nAs such, it may be desirable to establish therapies, treatments and/or interventions that address the loss of homeostasis and mis-regulation of bioactive molecules in order to prevent or treat a resulting disease.\n\nSome embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for the translation of a target biomolecule, and the miRNA can cause the bioavailability of the target mRNA to decrease because it is degraded and/or inactivated by the miRNA, thereby causing a decrease in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a cytokine. In some embodiments of the present disclosure, the target biomolecule is a cytokine such as IL-23.",
  "cpc": [
    "C12N 15/1136",
    "C12N 15/86",
    "C12N 2310/141",
    "C12N 2750/14143"
  ],
  "ipc": [
    "C12N 15/113",
    "C12N 15/86"
  ],
  "assignees": [
    "Wyvem Pharmaceuticals Inc"
  ],
  "inventors": [
    "Bradley G. Thompson"
  ],
  "filing_date": "2025-04-30",
  "publication_date": "2026-04-16",
  "priority_date": "2024-10-11",
  "application_number": "US-202519195132-A",
  "family_id": "99438054",
  "cited_by_count": 0
}